GENOMIND TO EXHIBIT AT TWO UPCOMING MENTAL HEALTH CONFERENCES
Staff to share latest advancements with attendees of APNA and Psych Congress.
Genomind, a personalized medicine company for neuropsychiatry, is excited to announce that company representatives will be attending and exhibiting at the American Psychiatric Nurses Association Annual Conference and the U.S. Psychiatric and Mental Health Congress, two respected conventions of mental health professionals that will occur this week.
Genomind will be on hand to share the most recent research and advancements in the field of personalized medicine, including their groundbreaking GeneceptTM Assay, a saliva-based test that quickly identifies biomarkers and genes that may influence or assist a clinician in developing a treatment plan for patients with depression and other neurological disorders. Genomind staff will share information with attendees on how such tests can be implemented into their practices, as well as how use of the test can often lead to better patient outcomes.
The American Psychiatric Nurses Association Annual Conference runs from November 7-10, 2012, at the David L. Lawrence Convention Center in Pittsburgh. The U.S. Psychiatric and Mental Health Congress will take place November 8-11, 2012, at the San Diego Convention Center.
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/products/assay.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Director of Marketing